BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its position in Core Laboratories N.V. (NYSE:CLB) by 80.7% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 17,917 shares of the oil and gas company’s stock after purchasing an additional 8,000 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Core Laboratories were worth $1,768,000 as of its most recent filing with the SEC.

A number of other large investors have also recently modified their holdings of the business. WCM Investment Management CA increased its stake in Core Laboratories by 2.5% in the third quarter. WCM Investment Management CA now owns 4,542,901 shares of the oil and gas company’s stock valued at $448,385,000 after purchasing an additional 109,726 shares in the last quarter. Vanguard Group Inc. increased its stake in Core Laboratories by 1.6% in the second quarter. Vanguard Group Inc. now owns 3,672,865 shares of the oil and gas company’s stock valued at $371,950,000 after purchasing an additional 56,807 shares in the last quarter. Sustainable Growth Advisers LP increased its stake in Core Laboratories by 36.9% in the second quarter. Sustainable Growth Advisers LP now owns 2,345,271 shares of the oil and gas company’s stock valued at $237,505,000 after purchasing an additional 632,263 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC increased its stake in Core Laboratories by 19.0% in the third quarter. Kayne Anderson Rudnick Investment Management LLC now owns 2,025,357 shares of the oil and gas company’s stock valued at $199,904,000 after purchasing an additional 323,357 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Core Laboratories by 14.9% in the third quarter. JPMorgan Chase & Co. now owns 935,695 shares of the oil and gas company’s stock valued at $91,904,000 after purchasing an additional 121,553 shares in the last quarter.

Several research firms have recently weighed in on CLB. Zacks Investment Research cut shares of Core Laboratories from a “hold” rating to a “sell” rating in a report on Tuesday, September 26th. Cowen set a $100.00 price target on shares of Core Laboratories and gave the company a “hold” rating in a report on Friday, October 6th. Piper Jaffray Companies set a $97.00 price target on shares of Core Laboratories and gave the company a “hold” rating in a report on Monday, October 23rd. Royal Bank of Canada reiterated a “buy” rating on shares of Core Laboratories in a report on Wednesday, October 18th. Finally, Loop Capital set a $115.00 price target on shares of Core Laboratories and gave the company a “buy” rating in a report on Thursday, December 7th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $110.40.

Core Laboratories N.V. (CLB) opened at $98.09 on Friday. The firm has a market cap of $4,330.38, a P/E ratio of 53.60 and a beta of 1.56. Core Laboratories N.V. has a 1-year low of $86.55 and a 1-year high of $125.83. The company has a quick ratio of 1.81, a current ratio of 2.18 and a debt-to-equity ratio of 1.53.

Core Laboratories (NYSE:CLB) last announced its earnings results on Monday, October 23rd. The oil and gas company reported $0.48 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.04. Core Laboratories had a net margin of 12.06% and a return on equity of 52.89%. The business had revenue of $166.20 million during the quarter, compared to analysts’ expectations of $160.94 million. During the same quarter in the prior year, the company posted $0.38 earnings per share. The firm’s revenue was up 1.4% on a year-over-year basis. sell-side analysts expect that Core Laboratories N.V. will post 1.99 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, November 21st. Investors of record on Friday, October 20th were issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 2.24%. The ex-dividend date of this dividend was Thursday, October 19th. Core Laboratories’s payout ratio is 126.44%.

COPYRIGHT VIOLATION NOTICE: “BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Acquires 8,000 Shares of Core Laboratories N.V. (CLB)” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/british-columbia-investment-management-corp-acquires-8000-shares-of-core-laboratories-n-v-clb/1769353.html.

Core Laboratories Profile

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories N.V. (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories (NYSE:CLB)

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.